CRISPR Therapeutics AG

NasdaqGM CRSP

CRISPR Therapeutics AG Price to Sales Ratio (P/S) on December 30, 2024: 16.36

CRISPR Therapeutics AG Price to Sales Ratio (P/S) is 16.36 on December 30, 2024, a 19.60% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • CRISPR Therapeutics AG 52-week high Price to Sales Ratio (P/S) is 25.57 on July 16, 2024, which is 56.27% above the current Price to Sales Ratio (P/S).
  • CRISPR Therapeutics AG 52-week low Price to Sales Ratio (P/S) is 13.13 on January 17, 2024, which is -19.78% below the current Price to Sales Ratio (P/S).
  • CRISPR Therapeutics AG average Price to Sales Ratio (P/S) for the last 52 weeks is 18.71.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
NasdaqGM: CRSP

CRISPR Therapeutics AG

CEO Dr. Samarth Kulkarni Ph.D.
IPO Date Oct. 19, 2016
Location Switzerland
Headquarters Baarerstrasse 14
Employees 407
Sector Health Care
Industries
Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Similar companies

VERV

Verve Therapeutics, Inc.

USD 5.25

-4.54%

SRPT

Sarepta Therapeutics, Inc.

USD 118.83

0.34%

REGN

Regeneron Pharmaceuticals, Inc.

USD 690.87

-3.63%

NTLA

Intellia Therapeutics, Inc.

USD 9.74

-3.08%

FATE

Fate Therapeutics, Inc.

USD 1.25

-3.10%

EDIT

Editas Medicine, Inc.

USD 1.14

-1.72%

BEAM

Beam Therapeutics Inc.

USD 23.30

-8.77%

CRBU

Caribou Biosciences, Inc.

USD 1.56

0.65%

KRYS

Krystal Biotech, Inc.

USD 142.64

-5.10%

StockViz Staff

January 15, 2025

Any question? Send us an email